SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

As we reflect on five years since the tumultuous start of the COVID pandemic (even if we just wish to forget it ever happened ...

Some 23% of people infected with SARS-CoV-2 between 2021 and 2023 developed long COVID, and in more than half of them the ...

Long COVID symptoms persisted for up to two years in more than half of the individuals who experienced the condition, according to new research published in BMC Medicine.

According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. Long ...

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations ...

A Stanford-led team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Half a decade since coronavirus SARS-CoV-2 plunged the world into a pandemic, the scars are still healing for those who lost ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

The following is a summary of “Association between SARS-CoV-2 and stroke: perspectives from a metaumbrella-review,” published ...

Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19 or ...